## Clinical Context This patient has an intermediate-thickness melanoma (Breslow 1.8 mm, Stage IB–IIA). The primary lesion has already been excised with diagnostic margins. The critical next step is accurate staging to determine prognosis and guide adjuvant therapy decisions. ## Why SLNB Is the Next Step **Key Point:** Sentinel lymph node biopsy (SLNB) is the standard of care for melanomas with Breslow thickness ≥1 mm (or ≥0.75 mm with high-risk features like ulceration or high mitotic rate) to stage the regional lymph nodes and identify occult nodal disease. **High-Yield:** SLNB is both prognostic and therapeutic: - Identifies patients with microscopic nodal metastases (Stage III) who benefit from adjuvant systemic therapy - Guides decisions on adjuvant immunotherapy (checkpoint inhibitors) or targeted therapy - Does NOT improve overall survival as a single intervention but enables risk stratification - Should be performed before wide local excision margins are finalized or shortly after primary excision ## Staging Algorithm for This Patient ```mermaid flowchart TD A[Melanoma Breslow 1.8 mm, no ulceration]:::outcome --> B{SLNB indicated?}:::decision B -->|Yes: thickness ≥1 mm| C[Perform SLNB]:::action C --> D{SLNB positive?}:::decision D -->|Negative| E[Stage IB-IIA<br/>Consider adjuvant ICI if high risk]:::outcome D -->|Positive| F[Stage III<br/>Adjuvant systemic therapy indicated]:::outcome B -->|No: thickness <1 mm| G[Clinical observation<br/>No SLNB]:::action ``` ## Why Other Options Are Premature or Incorrect | Option | Why It's Wrong | |--------|----------------| | Wide local excision alone | Does not stage regional nodes; misses occult nodal disease that would change management | | Immediate regional dissection | Performed only if SLNB is positive; elective dissection without nodal staging is not standard | | Adjuvant IFN-α without staging | Cannot determine candidacy for adjuvant therapy without knowing nodal status; IFN-α is rarely used now (replaced by checkpoint inhibitors) | **Clinical Pearl:** Modern melanoma management emphasizes nodal staging (SLNB) before adjuvant decisions. If SLNB is negative, observation or adjuvant immune checkpoint inhibitors (nivolumab, pembrolizumab) may be considered based on other high-risk features. If SLNB is positive, adjuvant systemic therapy (immunotherapy or targeted therapy) is strongly recommended. **Warning:** Do not confuse SLNB (diagnostic/staging) with elective lymph node dissection (therapeutic, only if nodes are involved). SLNB is minimally invasive and is the gateway to accurate staging. 
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.